Novel drug resistance mutations in HIV: recognition and clinical relevance.

During its spread among humans, HIV-1 has developed an extraordinary degree of genetic diversity. The pol region encoding for viral enzymes such as the reverse transcriptase and the protease, and the env region encoding for the viral glycoprotein gp41 are subjected not only to natural variation, but also to the selection pressure imposed by the pharmacologic treatment. Under these conditions in HIV-1 infected people, the virus is able to escape from antiviral drugs by accumulating mutations, either alone or in clusters. The patterns of mutations accumulated by HIV-1 under drug pressure are quite variable, depending on the backbone of virus strains, the level and type of pharmacologic pressure, and the length of therapy. To date, a high number of mutations in protease, reverse transcriptase, and gp41 have been associated with reduced susceptibility to the antiretroviral drugs currently available. However, a number of studies continuously highlight the existence of additional mutations beyond those currently known to be involved in the development of drug resistance in vivo. Most of these so-called "novel" mutations are involved in agonistic correlations with the classical drug resistance mutations on divergent evolutionary pathways, and are associated with an increased resistance to specific drugs. At the same time, the presence of some novel mutations at therapeutic failure has also been significantly associated with an increase of viremia, thus suggesting that they may also play a compensatory role leading to improved viral replication. Interestingly, some natural polymorphisms in drug-naive patients have been significantly associated with the development of drug resistance mutations at failure, thus suggesting their ability to decrease the genetic barrier to the development of drug resistance. In contrast, other novel mutations are negatively associated with specific antiviral treatment, showing negative interactions with relevant drug resistance mutations, and are associated with increased susceptibility to specific drugs. This article reviews the importance of recognition and the clinical relevance of novel mutations involved in resistance to the currently used antiretroviral drugs, discussing in particular the role of novel drug resistance mutations in the reverse transcriptase enzyme. Such novel mutations should be considered for improved prediction of clinical response to antiretroviral drugs and for assessing the efficacy of next-generation drugs.

[1]  E. Crespan,et al.  Drug Resistance Mutations in the Nucleotide Binding Pocket of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Differentially Affect the Phosphorolysis-Dependent Primer Unblocking Activity in the Presence of Stavudine and Zidovudine and Its Inhibition by Efavirenz , 2005, Antimicrobial Agents and Chemotherapy.

[2]  V. Calvez,et al.  Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure , 2004, Journal of medical virology.

[3]  John W. Mellors,et al.  A Novel Polymorphism at Codon 333 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Can Facilitate Dual Resistance to Zidovudine and l-2′,3′-Dideoxy-3′-Thiacytidine , 1998, Journal of Virology.

[4]  V. Calvez,et al.  Clinically Relevant Interpretation of Genotype and Relationship to Plasma Drug Concentrations for Resistance to Saquinavir-Ritonavir in Human Immunodeficiency Virus Type 1 Protease Inhibitor-Experienced Patients , 2004, Antimicrobial Agents and Chemotherapy.

[5]  M. Parniak,et al.  Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. , 1998, Biochemistry.

[6]  S. Sarafianos,et al.  Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases. , 2004, Current opinion in structural biology.

[7]  Jonathan M. Schapiro,et al.  Genotypic Changes in Human Immunodeficiency Virus Type 1 Protease Associated with Reduced Susceptibility and Virologic Response to the Protease Inhibitor Tipranavir , 2006, Journal of Virology.

[8]  O. Kirk,et al.  K65R with and without S68: A New Resistance Profile in Vivo Detected in Most Patients Failing Abacavir, Didanosine and Stavudine , 2003, Antiviral therapy.

[9]  S. Hammer,et al.  Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine , 2000, AIDS.

[10]  R. Pauwels,et al.  TMC125 Displays a High Genetic Barrier to the Development of Resistance: Evidence from In Vitro Selection Experiments , 2005, Journal of Virology.

[11]  V. Calvez,et al.  Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients , 2006, AIDS.

[12]  D. Richman,et al.  Reduced Susceptibility of Human Immunodeficiency Virus Type 1 (HIV-1) from Patients with Primary HIV Infection to Nonnucleoside Reverse Transcriptase Inhibitors Is Associated with Variation at Novel Amino Acid Sites , 2000, Journal of Virology.

[13]  M. Segondy,et al.  Prevalence and conditions of selection of the K65R mutation in the reverse transcriptase gene of HIV-1. , 2005, Journal of acquired immune deficiency syndromes.

[14]  D. Pillay,et al.  Emergence and Evolution of Enfuvirtide Resistance following Long-Term Therapy Involves Heptad Repeat 2 Mutations within gp41 , 2005, Antimicrobial Agents and Chemotherapy.

[15]  C. Moore,et al.  Evidence of HIV-1 Adaptation to HLA-Restricted Immune Responses at a Population Level , 2002, Science.

[16]  M. Wainberg,et al.  Diminished Representation of HIV-1 Variants Containing Select Drug Resistance-Conferring Mutations in Primary HIV-1 Infection , 2004, Journal of acquired immune deficiency syndromes.

[17]  M. Wainberg,et al.  The M184V mutation in HIV-1 reverse transcriptase reduces the restoration of wild-type replication by attenuated viruses , 2002, AIDS.

[18]  Francesca Ceccherini-Silberstein,et al.  Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort. , 2004, The Journal of infectious diseases.

[19]  P. Ravindran,et al.  Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[20]  W. Heneine,et al.  Evidence of a Role for the Q151L Mutation and the Viral Background in Development of Multiple Dideoxynucleoside-Resistant Human Immunodeficiency Virus Type 1 , 2000, Journal of Virology.

[21]  J. Corbeil,et al.  Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy , 1994, Journal of virology.

[22]  E A Emini,et al.  Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors. , 1992, The Journal of biological chemistry.

[23]  J. Mellors,et al.  Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors , 2006, AIDS.

[24]  B. Preston,et al.  Purifying Selection Masks the Mutational Flexibility of HIV-1 Reverse Transcriptase* , 2004, Journal of Biological Chemistry.

[25]  Thomas Lengauer,et al.  Involvement of Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutations in the Regulation of Resistance to Nucleoside Inhibitors , 2006, Journal of Virology.

[26]  Maurizio Zazzi,et al.  Gln145Met/Leu Changes in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Resistance to Nucleoside and Nonnucleoside Analogs and Impair Virus Replication , 2004, Antimicrobial Agents and Chemotherapy.

[27]  C. Tinelli,et al.  HIV-1 resistance to dideoxynucleoside reverse transcriptase inhibitors: genotypic-phenotypic correlations. , 2004, Journal of acquired immune deficiency syndromes.

[28]  B. Clotet,et al.  Thymidine Analogue Mutation Profiles: Factors Associated with Acquiring Specific Profiles and their Impact on the Virological Response to Therapy , 2005, Antiviral therapy.

[29]  D. Richman,et al.  2022 update of the drug resistance mutations in HIV-1. , 2022, Topics in antiviral medicine.

[30]  B. Rodés,et al.  Prevalence of G333D/E in naive and pretreated HIV-infected patients. , 2002, AIDS research and human retroviruses.

[31]  Samantha MaWhinney,et al.  Phenotypic and Genotypic Analysis of Biologically Cloned Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Zidovudine and Lamivudine , 2002, Antimicrobial Agents and Chemotherapy.

[32]  Ronald J Bosch,et al.  Genetic correlates of efavirenz hypersusceptibility , 2004, AIDS.

[33]  W. Wester,et al.  Mutations and Polymorphisms Associated with Antiretroviral Drugs in HIV-1C-Infected African Patients , 2004, Antiviral chemistry & chemotherapy.

[34]  H. Mitsuya,et al.  Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy. , 1998, The Journal of infectious diseases.

[35]  Thomas D. Wu,et al.  Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors , 2003, AIDS.

[36]  A. D. De Groot,et al.  An interactive Web site providing major histocompatibility ligand predictions: application to HIV research. , 1997, AIDS research and human retroviruses.

[37]  B. Berkhout,et al.  Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect. , 2001, Virology.

[38]  S. Lo Caputo,et al.  Impact of unreported HIV‐1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non‐nucleoside inhibitors , 2006, Journal of medical virology.

[39]  F. Ceccherini‐Silberstein,et al.  Clinical and genotypic correlates of mutation K65R in HIV‐infected patients failing regimens not including tenofovir , 2006, Journal of medical virology.

[40]  Thomas Lengauer,et al.  Characterization of Novel HIV Drug Resistance Mutations Using Clustering, Multidimensional Scaling and SVM-Based Feature Ranking , 2005, PKDD.

[41]  R. Haubrich,et al.  The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis , 2002, AIDS.

[42]  R. Schinazi,et al.  Differential Removal of Thymidine Nucleotide Analogues from Blocked DNA Chains by Human Immunodeficiency Virus Reverse Transcriptase in the Presence of Physiological Concentrations of 2′-Deoxynucleoside Triphosphates , 2000, Antimicrobial Agents and Chemotherapy.

[43]  A. So,et al.  Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[44]  C. Moore,et al.  Interactive Selective Pressures of Hla-Restricted Immune Responses and Antiretroviral Drugs on HIV-1 , 2005, Antiviral therapy.

[45]  V. Pathak,et al.  Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[46]  D. Richman,et al.  Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. , 2000, The Journal of infectious diseases.

[47]  Valentina Svicher,et al.  Novel Human Immunodeficiency Virus Type 1 Protease Mutations Potentially Involved in Resistance to Protease Inhibitors , 2005, Antimicrobial Agents and Chemotherapy.

[48]  A. Antinori,et al.  Using a Database of HIV Patients Undergoing Genotypic Resistance Test after Haart Failure to Understand the Dynamics of M184V Mutation , 2003, Antiviral therapy.

[49]  D. Richman,et al.  Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy , 2000, AIDS.

[50]  K. Hertogs,et al.  Correlation of Phenotypic Zidovudine Resistance with Mutational Patterns in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1: Interpretation of Established Mutations and Characterization of New Polymorphisms at Codons 208, 211, and 214 , 2003, Antimicrobial Agents and Chemotherapy.

[51]  T. Harrer,et al.  Multiple dideoxynucleoside analogue‐resistant (MddNR) HIV‐1 strains isolated from patients from different European countries , 1998, AIDS.

[52]  Robert W. Shafer,et al.  Drug Resistance and Heterogeneous Long-Term Virologic Responses of Human Immunodeficiency Virus Type 1-Infected Subjects to Zidovudine and Didanosine Combination Therapy , 1995 .

[53]  S D Kemp,et al.  Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). , 1989, Science.

[54]  M. Mouroux,et al.  Mutations in the human immunodeficiency virus type 1 reverse transcriptase gene observed in stavudine and didanosine strains obtained by in vitro passages. , 1998, Research in virology.

[55]  Daniel R Kuritzkes,et al.  Effect of the Q207D Mutation in HIV Type 1 Reverse Transcriptase on Zidovudine Susceptibility and Replicative Fitness , 2005, Journal of acquired immune deficiency syndromes.

[56]  F. Ceccherini‐Silberstein,et al.  High Sequence Conservation of Human Immunodeficiency Virus Type 1 Reverse Transcriptase under Drug Pressure despite the Continuous Appearance of Mutations , 2005, Journal of Virology.

[57]  Tommy F. Liu,et al.  HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. , 2005, The Journal of infectious diseases.

[58]  Laura Galli,et al.  Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study) , 2006, AIDS.

[59]  R. Shafer,et al.  Genotypic predictors of human immunodeficiency virus type 1 drug resistance , 2006, Proceedings of the National Academy of Sciences.

[60]  M. Wulfsohn,et al.  Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. , 2004, The Journal of infectious diseases.

[61]  P. Narciso,et al.  Failure of stavudine‐lamivudine combination therapy in antiretroviral‐naive patients with AZT‐Like HIV‐1 resistance mutations , 2001, Journal of medical virology.